Serial Number | 98547760 |
Word Mark | INOGRAFT BIOTHERAPEUTICS |
Filing Date | Monday, May 13, 2024 |
Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
Status Date | Tuesday, February 18, 2025 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, December 24, 2024 |
Goods and Services | Stem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes |
Goods and Services | Stem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use |
NOT AVAILABLE | "BIOTHERAPEUTICS" |
Goods and Services | Research and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants |
International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
US Class Codes | 001, 005, 006, 010, 026, 046 |
Class Status Code | 6 - Active |
Class Status Date | Monday, May 13, 2024 |
Primary Code | 001 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Monday, May 13, 2024 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Monday, May 13, 2024 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Inograft Biotherapeutics, Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Palo Alto, CA 94304 |
Party Name | Inograft Biotherapeutics, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Palo Alto, CA 94304 |
Event Date | Event Description |
Monday, May 13, 2024 | NEW APPLICATION ENTERED |
Wednesday, November 13, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Tuesday, December 3, 2024 | EXAMINERS AMENDMENT E-MAILED |
Tuesday, November 26, 2024 | ASSIGNED TO EXAMINER |
Tuesday, December 3, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Tuesday, December 3, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Tuesday, December 3, 2024 | EXAMINERS AMENDMENT -WRITTEN |
Tuesday, December 3, 2024 | EXAMINER'S AMENDMENT ENTERED |
Wednesday, December 18, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, December 24, 2024 | PUBLISHED FOR OPPOSITION |
Tuesday, December 24, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, February 18, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |